{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:34:56Z","timestamp":1793104496770,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.atherosclerosis.2014.10.099","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T22:06:23Z","timestamp":1414706783000},"page":"705-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["ETC-1002: A future option for lipid disorders?"],"prefix":"10.1016","volume":"237","author":[{"given":"Dragana","family":"Nikolic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib2","series-title":"Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib3","unstructured":"Esperion Therapeutics, Inc., Available from: http:\/\/www.esperion.com\/therapies-progress\/clinical-studies\/."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib4","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors: an emerging lipid-lowering therapy?","author":"Dragan","year":"2014","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11255-014-0657-6","article-title":"Lipid, blood pressure and kidney update 2013","volume":"46","author":"Banach","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib6","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.2174\/13816128113199990324","article-title":"Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?","volume":"19","author":"Rizzo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.5114\/aoms.2012.30281","article-title":"Lipid-lowering therapies and achievement of LDL-cholesterol targets","volume":"8","author":"Rizzo","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib8","unstructured":"Esperion Therapeutics, Inc. 2014. Available from: http:\/\/files.shareholder.com\/downloads\/AMDA-1UZG66\/0x0x744443\/0A0F2E62-8FAD-443C-B531-0F768179B9F7\/ESPR_Annual_Report_2014_040214_FINAL__FINAL.PDF."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib9","unstructured":"Understanding Key Pathways. Available from: http:\/\/www.esperion.com\/our-pathways-approach\/understanding-key-pathways\/."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib11","series-title":"Atherosclerosis, Thrombosis, and Vascular Biology Scientific Sessions; April 28\u201330; Chicago, IL","article-title":"ETC-1002 was safe, well-tolerated, and reduced LDL-C in a phase I multiple-dose study of subjects with mild dyslipidemia","author":"MacDougall","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib12","unstructured":"Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-etc-1002 (NCT02044627). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02044627?term=%22ETC-1002%22&rank=6."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/ATVBAHA.114.303171","article-title":"Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus","volume":"34","author":"Goldberg","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib15","unstructured":"A Study of the Efficacy and Safety of ETC-1002 in Subjects with Statin Intolerance (NCT01751984). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01751984?term=%22ETC-1002%22&rank=9."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib16","series-title":"ETC-1002: a Novel Small Molecule Inhibitor of Lipogenesis Improves Plasma Lipid Profile and Inhibits Atherosclerosis Progression in LDLr\u2212\/\u2212 Mouse by a Lipid-dependent and Independent Mechanism","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib17","series-title":"A\u00a0Novel Small Molecule, ETC-1002, Lowers Proatherogenic Lipoproteins, Reduces Adiposity, and Improves Hepatic Steatosis in a Hyperlipidemic Hamster Model","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib18","series-title":"ETC-1002 Reduces Circulating and Hepatic Triglyceride Content and Improves Glycemic Control in KKAy Mice","year":"2011"},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib19","unstructured":"A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects (NCT01485146). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01485146?term=%22ETC-1002%22&rank=7."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib20","unstructured":"A Multiple Ascending Dose Study of ETC-1002 in Subjects with Mild Dyslipidemia (NCT01105598). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01105598?term=%22ETC-1002%22&rank=3."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib21","unstructured":"Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients (NCT01941836). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01941836?term=%22ETC-1002%22&rank=5."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib23","unstructured":"A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects with Hypercholesterolemia (NCT01779453). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01779453?term=%22ETC-1002%22&rank=8."},{"key":"10.1016\/j.atherosclerosis.2014.10.099_bib24","unstructured":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy (NCT02072161). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02072161?term=%22ETC-1002%22&rank=4."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014015548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014015548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T23:24:07Z","timestamp":1538090647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014015548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0021915014015548"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.099","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ETC-1002: A future option for lipid disorders?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}